CHROM. 3770

# REFERENCE HIGH-EFFICIENCY NONPOLAR PACKED COLUMNS FOR THE GAS-LIQUID CHROMATOGRAPHY OF NANOGRAM AMOUNTS OF STEROIDS 

PART I. RETENTION TIME DATA*

FRANTZ A. VANDENHEUVEL AND A. SALLY COURT**
Animal Research Institute, Research Branch, Canada Department of Agrictelture, Ottaze, Ont. (Canada)
(Received August 1 5th, r968)


#### Abstract

SUMMARY The preparation and conditioning of reproducible, long-lasting, 6000 theoretical plate nonpolar columns are described. Retention data of TMS derivatives at 215,230 and $240^{\circ}$ are given for 140 standard steroids of the androstane, pregnane and cholestane series. Additive incremental factors permitting a precise prediction of retention times are given for many specific structural features and functional groups. Operational conditions that permit highly reproducible results with nanogram amounts of steroids are described and discussed.


## INTRODUCTION

The analysis of total steroids extracted from most biological materials offer difficult problems which arise from the number, structural variety, similarity in physical properties and very low concentrations of many components. Such problems can be solved by a combined thin-layer and gas-liquid chromatography (TLC-GLC) method ${ }^{1-8}$; by this method, total steroids are first separated in several fractions which are characterized by molecules containing specific numbers of hydroxyl and carbonyl groups. Each of these fractions is then resolved by GLC.

Routine examination of TLC fractions by GLC, whether for the purpose of component identification of quantification, is particularly efficient and reliable with columns of high resolving power when these columns show unaltered characteristics over a long period of time.

The present paper describes the preparation and detailed properties of readily reproduced nonpolar columns which in three years of almost continuous use have

[^0]consistently displayed identical characteristics. Their resolving power, obtained from the Keulemans expression ${ }^{9}$ corresponds, for example, to 5500 and 6150 theoretical plates for the trimethylsilyl ether (TMS) derivatives of cholesterol and stigmasterol, respectively.

With such columns, retention times are reproducible enough to permit unequivocal discrimination between compounds which differ very little in this respect; a precise prediction of retention times from structure-dependent increments ${ }^{1,2}$ can be made for the entire life-span of the columns.

Furthermore, reliable quantitative work can be made on the basis of calibration curves which remain valid over long periods of time.

These important advantages are obtained under simple operational conditions provided that the conditions are used consistently.

EXPERIMENTAL

## Equipment

Perkin Elmer Soo gas chromatograph equipped with dual flame ionization detector fitted with ceramic jets.

Perkin Elmer goo gas chromatograph.
Philips PR 2500 recorder, I mV full scale.
Perkin Elmer No. 194 Printing Integrator.
Maximum signal-to-noise ratio was obtained as follows: Chromatograph and recorder were connected to separate electrical power lines, that used for the recorder being free of noise-generating equipment. Recorder gain was adjusted for incipient "hunting" by pen-drive motor, and the chromatograph chassis was earthed by connecting to a water main. Under full operational conditions at attenuation $\times \mathrm{I}$, the base line was consistently straight with occasional transient deflections not exceeding $0.5 \%$ of the chart span.

The oven of the P.E. 800 instrument was fitted with a $200-260^{\circ}$ Anschütz thermometer (Fisher $\mathrm{I}_{5}-\mathrm{I} 65 \mathrm{E}$ ) calibrated in situ and under operating conditions against a precision resistance thermometer.

## Materials

JXR, $3 \%$ dimethylpolysiloxane on 100/Izo Gas Chrom Q, prepared by, and received from Dr. W. Supina, now with Supelco, Inc., Bellefonte, Pa. 16823, U.S.A. Hexamethyldisilazane and trimethylchlorosilane, redistilled.
$\mathrm{CS}_{2}$, Fisher No. C 184 reagent.
Standard steroids from Steraloids Inc., P.O. Box 127, Pawling, N.Y. 12564.
Standard steroids from the Steroid Reference Collection (cf.Acknowledgements) indicated by S.R.C. in Tables VIII and IX.

Steroids obtained by reduction of standard steroids (cf. Discussion and Tables VIII and IX).

## Methods

Preparing columns. Two 9 ft . straight lengths of $\mathrm{I} / 8 \mathrm{in}$. O.D. stainless steel tubing cut from the same stock were cleaned internally by connecting one end with polyethylene tubing to a partially evacuated flask and slowly aspirating chloroform-
methanol (2:I) through a polyethylene tubing connected to the other end. The tubes were dried with a stream of $\mathrm{N}_{2}$ and clamped vertically side by side at about 2 in . from each other. Bottom ends of the tubes were plugged; each of the upper ends were connected by a short section of polyethylene tubing to one of twin funnels described in Fig. IA.


Fig. 1. (A) Glass funnel for the filling of columns. $f=$ Graduated body, 14.3 mm I.D.; $o=$ outlet, r. 5 mm I.D., 18 in . O.D., 20 mm long; $y=$ polyethylene connective tubing; u = column. Both funnel and column are clamped on the same support. (B) Three methods for column plugging: (a) Solid plug method ( $w=$ fine Pyrex glass wool, Corning No. 3950, silanized; $h=r-m m$ diam. hole; $p=$ stainless steel plug). (b) Screw method ( $w$, as above; $s=3-48$ NC screw; $h=1-m m$ diam. hole; a size $3-48$ NC tap is used to thread the column). (c) Porous clisk method ( $d=$ stainless steel porous clisk, Perkin Elmer Cat. No. oo8-rar6).

Four grams of $3 \%$ JXR on roo-120 mesh Gas Chrom $Q$ were placed in each of the funnels and the columns were tapped with a pencil about their middle section. Rapid, alternated tapping between the two columns caused just enough vibration to make the powder flow evenly and at the same speed, from both funnels. Packing was completed when levels of excess powder in the funnels remained constant after sustained tapping progressing from the bottom to the top of the columns. The funnels were disconnected carefully and the weights of excess powder were compared to detect a possible discrepancy. On the average, each column contained 3.60 g of packing material of density $0.3 \mathrm{~g} / \mathrm{ml}$.

Both ends of the columns were then plugged. Three ways of effecting this operation are described in Fig. IB and related caption. In plugging columns by methods a and b (Fig. TB) the packing material in completely filled columns was first pushed I/4 in. inside with a metal rod. The resulting space was then filled completely with fine silanized glass wool. Insertion of either plug, p, or screw, $s$, then resulted in further compression of the wool. When method $b$ was used, the column ends were threaded over $\mathrm{I} / 2 \mathrm{in}$. before cleaning and filling the tubes. With method c , damage to the pores of disks, d, was avoided by pressing (rather than tapping) the disks in position. In all cases, damage to the terminal $I / 2 \mathrm{in}$. of outer surface was avoided to permit a tight fitting of Swagelock connectors. The columns were coiled on a 2 in. O:D. mandrel.

The packed columns were connected to the gas chromatograph by their inlet end; connection to the detector was absolutely avoided. Helium flow through each column was adjusted to $60 \mathrm{ml} / \mathrm{min}$. with a bubble meter. The gas flow was then completely cut off and the conditioning schedule shown in Table I was observed.

TABLE I
CONDITIONING ${ }^{\text {a }}$ SCHEDULE FOR TWIN 9 -FOOT, I/8 INCH OUTER DIAMETER HIGH-EFFICIENCY JXR COLUMNS

| Tine <br> (h) | Temperature ${ }^{\text {b }}$ ( ${ }^{\circ} \mathrm{C}$ ) | FIelium flow rate. ( $\mathrm{ml} / \mathrm{min}$ ) |
| :---: | :---: | :---: |
| $\bigcirc$ | Room temperature | $\bigcirc$ |
| 8 | 250 | 0 |
| 24 | 2.50 | $\bigcirc$ |
| 32 | 300 | 0 |
| 48 | 300 | 0 |
| 49 | 250 | 0 |
| 52 | 300 | 30 |
| 72 | 300 | 30 |
| 73 | 300 | 60 |
| 76 | Room temperature | 60 |

[^1]
## Setiing-up conditions

Adjustment of conditions permitting duplication with any JXR column of retention times listed for $230^{\circ}$ in Tables II-IX was made as follows. A standard CS 2 solution containing 30 ng of TMS derivative of $3 \beta$-hydroxy- $5 \alpha$-androstane ( $3 \beta$ androstanol $)^{4,5}$ and 50 ng of $5 \alpha$-cholestane per $\mu 1$ was prepared. With the oven temperature set at $230^{\circ}$, standard conditions described in Table II were used. Two microliters of the standard solution were injected. Corrected retention times of both compounds were recorded with attenuation setting $\times$ Io for the P.E. 800 instrument ( $\times 1, \times 40$ with P.E. 900). If the ratio of the retention time of cholestane to that of the derivative of $3 \beta$-androstanol was higher than 3.575 ( $3.575=680 /$ 190) the temperature was increased by $0.05^{\circ}$ for everyo.00I units difference in this ratio; conversely, the temperature was lowered by this amount when the observed ratio was smaller than 3.575 . The helium flow was then adjusted to bring the retention time of cholestane to 6.80 min . If the retention time ratio still differed from the correct one the operation was repeated. It should be noted that the retention time of cholestane varied by $3.7 \%$ per ${ }^{\circ} \mathrm{C}$, whereas the corresponding variation for $3 \beta$-androstane TMS was $3.2 \%$ only.

Preparing TMS derivatives. Up to I mg of hydroxylated steroid were reacted in a glass-stoppered flask with $50 \mu \mathrm{l}$ of hexamethyldisilazane and $50 \mu \mathrm{l}$ of $10 \%$ trimethylchlorosilane in chloroform ( $\mathrm{v} / \mathrm{v}$ ), the reagents being added in that order. With larger amounts of steroids correspondingly larger volumes of reagents were used. Brief
mixing by stirring or vibration was applied after each addition; the top of the stopper was greased with silicone lubricant. If the steroid had been obtained by evaporating a solution, moisture and last traces of solvent were removed before adding the reagents by leaving the flask for 2 h in an evacuated dessicator over $\mathrm{P}_{2} \mathrm{O}_{5}$.

The reaction mixture was left at room temperature for at least $3 \mathrm{~h}^{1,2}$. Excess solvent and reagents were removed as described in ref. 2. $\mathrm{CS}_{2}$, or a solution in $\mathrm{CS}_{2}$ of the selected standard was then added to the flask contents. These, including residual ammonium chloride formed in the reaction, dissolved completely.

Standard solutions. It will be shown in Part $\mathrm{II}^{17}$ of the present series of papers that the retention time of a given steroid under a given set of conditions is minimum when the quantity injected lies within a range which is specific for the structural group to which the steroid belongs.

Concentrations in the standard solutions used to produce the present data were such that $2 \mu$ of injected solution contained amounts of individual steroids falling within the specific range for constant, minimum retention time. These concentrations were also adjusted to produce peaks of roughly comparable size at the same attenuation setting.

To begin with, solutions containing the TMS derivative of single steroids along with at least one standard steroid were prepared and the retention times were determined at $230^{\circ}$ under adjusted operational conditions ( $c f$. above). Next, several mixtures containing from 20 to 30 steroids were prepared and treated with TMS reagents. The components were selected according to the known retention times so as to produce an uninterrupted series of peaks with minimum overlap when injected together. An example of chromatograms thus obtained is given in Fig. 2. Most steroids were included in at least two of the twelve different solutions that were prepared. Most of


Fig. 2. Chromatogram of standard steroid mixture at $230^{\circ}$. Conditions: cf. Tables II-IX. The components, designated by peak number, group and number in group, and Table number, were as follows: $\mathrm{I}=\mathrm{Az}, \mathrm{II} ; 2=\mathrm{A}_{3}, \mathrm{II} ; 3=\mathrm{C} 2, \mathrm{IV} ; 4=\mathrm{Dr}, \mathrm{V} ; 5=\mathrm{C}_{4}, \mathrm{IV} ; 6=\mathrm{D} 5, \mathrm{~V} ; 7=\mathrm{D}, \mathrm{V} ; 8=$

 $22=C x 6, I V$. Some of the amounts injected were, in nanograms: A2, $1.0 ; C 2,6.0 ; D_{15}, 20.0 ; G 1$, 30.5 ; $\mathrm{C}_{7}, 50 . \mathrm{x}$. Note separation of peak 19 (cholesterol, $\mathrm{C}_{7}$ ) and peak 20 (desmosterol, C9) on JXR column of 5500 theoretical plates (for cholesterol).
six steroids considered as potential internal standards in future work were included in all solutions. These were the TMS derivatives of $3 \alpha$-hydroxy- $5 \alpha$-androstane, $3 \alpha, 20 \alpha-$ hydroxy-5 $\beta$-pregnane (pregnanediol), $3 \beta$-hydroxycholest-5-ene (cholesterol), and the hydrocarbons $5 \alpha$-pregnane, $5 \alpha$-cholestane and stigmastane.

Using these solutions it was possible to obtain readily the retention times of a large number of steroids and to correlate these retention times to those of the above six key steroids.

It was observed that standard solutions of TMS derivatives prepared in the way described were stable under the following simple conditions ${ }^{1,2}$ : cold storage ( $-5^{\circ}$ ) between uses of at least 5 ml of solution in narrow-necked flasks fitted with groundglass stoppers lubricated with silicone grease; bringing to room temperature before opening a flask and minimizing exposure to moisture during use.

## Retention time data

A Precision-Scientific "Time It" instrument giving a digital reading to the nearest $I /$ Iooth of a minute was started (zero time) when a rapid deflection of the recorder pen following injection marked the solvent vapour surge into the detector. This occurred 23 sec . after injections at $230^{\circ}$, for example. For each of the successive peaks, time was read as the recorder pen just left the peak apex on its downward course. Thus "corrected" retention times were recorded within $\pm I / 100 t h$ of a minute.

The retention time data listed in Tables II to IX were obtained with the P.E. Soo chromatographer at $215.0,230.0$, and $240.0^{\circ}$ with the 3 -year-old columns. In these experiments the temperature, as indicated by the Anschütz thermometer, never varied more than $\pm 0 . I^{\circ}$ in the course of each experiment ( $\approx 30$ min). Very slow cyclic variations within $\pm 0.25^{\circ}$ were observed in the course of many hours: thus the temperature from experiment to experiment varied to some extent and the observed retention times varied accordingly.

However, when observed retention times were normalized to the nominal, or set temperature of the experiment, normalized retention times agreed within $\pm 0.2 \%$. Normalization was obtained by multiplying an observed value by the ratio $t^{\prime} r_{n}^{s} / t^{\prime} r_{e}^{s}$

ABLE II
JRRECTED RETENTION TIMES' $t^{\prime}$ r AND LOG $t^{\prime} R$ OF STEROIDS ON JNR COLUMNS AT 215, 230 AND $240^{\circ}$
roup A-hydrocarbons

| 0. | Compound | Trivial name | $\underline{70^{2} \times t^{\prime} R(m i n 2)}$ |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $215{ }^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ |
| : | $5 \beta$-Androstane | Etiocholane | II3 | 77 | 61 | 2053 | 1887 | ${ }^{1784}$ |
| : | $5 \alpha$-Androstane | Androstane | 124 | 84 | 66 | 2093 | 1924 | ISI9 |
| i | 50 -Pregnane | Allopregnane | 2 IS | 141 | 108 | 2338 | 2150 | 2033 |
| + | $5 \beta$-Cholestane | Coprostane | 1089 | 620 | 435 | 3037 | 2792 | 2638 |
| ; | $5 \alpha$-Cholest-z-ene |  | 1175 | 667 | 469 | 3070 | $2 \mathrm{Sz4}$ | 2671 |
| ; | Cholest-5-ene | Cholestene | 1200 | 678 | 475 | 3079 | 2831 | 2676 |
| , | 5 $\alpha$-Cholestane | : Cholestane | 1200 | 680 | 477 | 3079 | 2833 | 2678 |
| i | Cholesta-3,5-diene |  | 1332 | 748 | 522 | 3124 | 2874 | 2717 |
| 1 | $5 \alpha, 24 \beta$-Ethyl-cholestane | Stigmastane | 2038 | IIIS | 763 | 3309 | 3048 | 2882 |

[^2]TABLE III
CORRECTED RETENTION TIMES品 $t^{\prime} n$ AND LOG $t^{\prime} n$ OF STEROIDS ON JXR COLUMNS AT 215,230 AND $240^{\circ}$ group B-mono- and polyietones

| No. | Compound | Trivial name | $10^{2} \times t^{\prime} R(m i n)$ |  |  | $10^{3} \times \log t^{\prime} \pi$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $215{ }^{\circ}$ | $230^{\circ}$ | $2.40^{\circ}$ | $215{ }^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ |
| 1 | $5 \alpha$-Androstan-17-one | Anclrostanone | 24 T | 155 | 119 | 2382 | 2190 | 2076 |
| 2 | $5 \alpha$-Androstan-3-one |  | 264 | 169 | 127 | 2421 | 2228 | $2 \mathrm{IO}_{4}$ |
| 3 | $5 \beta$-Pregnan-3-one |  | 429 | 262 | 194 | 2632 | 2418 | 2288 |
| 4 | 5 $\beta$-Androstan-17-one |  | 468 | 288 | 213 | 2670 | 2459 | 2328 |
| 5 | Androst-4-ene-3,17-dione |  | 635 | 384 | 287 | 2803 | 2584 | 2458 |
| 6 | Anclrosta-1,4-diene-3, 7 -dione |  | 690 | 416 | 304 | 2839 | 2619 | 2483 |
| 7 | 5 $\beta$-Pregnane-3,20-dione | Prenanedione | 760 | 449 | 325 | 2880 | 2652 | 2512 |
| 8 | Androst-4-ene-3,11, I 7 -trione |  | 798 | 475 | 34 T | 2902 | 2676 | 2533 |
| 9 | $5 \alpha$-Pregnane-3,20-dione |  | S40 | 497 | 360 | 2924 | 2696 | 2556 |
| to | 5 $\beta$-Pregnanc-3,11, 20-trione |  | 960 | 572 | 411 | 2982 | 2757 | 2614 |
| 1 I | Pregn-4-ene-3,20-dione | Progesterone | 1030 | 613 | 440 | 3013 | 2788 | 2643 |
| 12 | 5 $\alpha$-Pregnane-3,11, 20-trione |  | 1090 | 649 | 467 | 3038 | 2812 | 2669 |
| 13 | $5 \beta$-Cholestan-3-one | Coprostanone | 2340 | 1255 | 860 | 3369 | 3098 | 2934 |
| 14. | 5 $\alpha$-Cholestan-3-one | Cholestanone | 2605 | 1390 | 951 | 3415 | 3143 | 2977 |
| 15 | Cholesta-3,5-dien-7-one |  | 2875 | 1525 | 1039 | 3458 | 3183 | 3 Or 7 |
| 16 | Cholesta-4,6-clien-3-one |  | 3497 | 1905 | 1224 | 3544 | 3256 | 3087 |

a Operational conditions: cf. Table II.
where $t^{\prime} T_{c}^{s}$ is the retention time observed in the same experiment for an internal standard included in the mixture, and $t^{\prime} y_{n}^{s}$ its retention time at the nominal temperature of the experiment. In most experiments normalization of the data could be effected by using several internal standards. In no case were the necessary corrections larger than $\mathrm{I} \%$.

From retention time logarithms listed in Tables II to IX incremental factors of these logarithms shown in Tables X and XII were computed. The values obtained for specific functional groups or combination of groups were often averages derived from data on several steroids which included the relevant structural features. Variations observed for individual values of such increments were usually less than $I \%$; thus retention times could be accurately predicted from the structural formulae simply by adding up appropriate increments ${ }^{1,2}$. Examples applying to androstane-and pregnanediols are given in Table XI. Table XII gives incremental values for many combinations of structural features concerning sterols.

Incremental values of this type were first described by Knights and Thomas ${ }^{9}$. Their use in the detection and structural identification of steroids will be discussed in detail in Part II $^{17}$ of the present series of papers. Quantification problems at the nanogram level will be discussed in Part III.

## DISCUSSION

The importance of minimizing vibration during the packing of columns must be stressed. By tapping the columns as described the flow of packing material was slow and even; air pockets did not form, the powder packed almost maximally, and about 20 min were required to fill the columns. Further tapping usually resulted in some increase in packing density. Excess vibration, on the other hand, did not increase
TABLE IV
CORRECTED RETENTION TMMES $i^{\prime}{ }^{\prime}$ AND LOG $i^{\prime}$ OF TRIMETHYLSILYL DERIVATIVES OF HYDROXYLATED STEROIDS ON JXR COLUNNS AT 2I5, 230 AND $240^{\circ}$ GROUP C-MONOHYDROXY COMPOUNDS

| No. | Compound | Trivial name | $\left.10^{2} \times t^{\prime}{ }^{(m i n}\right)$ |  |  | $10^{3} \times \log t^{\prime}{ }_{R}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ |
| $\underline{1}$ | 3 $\alpha$-Hydroxy-5 $\alpha$-androstane | $3 \alpha^{2}$-Androstanol | 239 | 150 | 113 | 2378 | 2175 | 2053 |
| 2 | 3 $\beta$-Hydroxy-5 $\alpha$-androstane | 3 $\beta$-Androstanol | 305 | 190 | 141 | 2484 | 2278 | 2149 |
| 3 | $3 \alpha$-Hydroxy-5 $\beta$-pregnane | $3 \alpha$-Pregnanol | 444 | 266 | 192 | 2647 | 2424 | 2283 |
| 4 | 3 $\beta$-Hydroxy-5 $\alpha$-pregnane | 3 $\beta$-Allopregnanol | $54^{\circ}$ | 321 | 232 | 2732 | 2506 | 2365 |
| 5 | $3 \beta$-Hydroxy-5 $\beta$-cholestane | $3 \beta$-Coprostanol | 2305 | 1227 | 825 | 3362 | 3088 | 2916 |
| 6 | $3 \alpha-\mathrm{Hydroxy}$ - $5 \beta$-cholestane | 3 $\alpha$-Coprostanol | 2439 | 1268 | 850 | 3387 | 3103 | 2929 |
| 7 | $3 \beta$-Hydroxycholest-5-ene | Cholesterol | 2936 | 1536 | 1022 | 3467 | 3186 | 3009 |
| 8 | $3 \beta$-Hydroxy-5 $\alpha$-cholestane | $3 \beta$-Cholestanol | 3005 | 1574 | 1047 | 3477 | 3197 | 3020 |
| 9 | $3 \beta$-Hydroxycholesta-5,24-diene | Desmosterol | 3217 | 1673 | 1108 | 3507 | 3224 | 3044 |
| 10 | $3 \beta$-Hydroxycholesta-5,7-diene | 7-Dehydrocholesterol | 3250 | 1677 | 1117 | 3511 | 3225 | 3048 |
| II | $3 \beta$-Hydroxycholest-7-ene | Lathosterol ${ }^{\text {b }}$ | 3360 | 1750 | 1150 | 3526 | 3243 | 3060 |
| 12 | $3 \beta$-Hydroxycholesta-8,24-diene | Zymosterol ${ }^{\text {b }}$ | 3365 | 1754 | 1155 | 3527 | 3244 | 3063 |
| 13 | $3 \beta$-Hydroxycholesta-5,7,24-triene | b | 3540 | 1841 | 1200 | 3549 | 3265 | 3089 |
| 14 | $3 \beta$-Hydroxy-24 $\beta$-methylcholesta-5,7,22-triene | Ergosterol | 3640 | 1885 | 1268 | 3561 | 3275 | 3103 |
| 15 | 3 $\beta$-Hydroxy-24 $\alpha$-methylcholest-5-ene | Campesterol | 3905 | 1998 | 1316 | 3591 | 3301 | 3119 |
| 16 | $3 \beta$-Hydroxy-24 $\beta$-ethylcholesta-5,22-diene | Stigmasterol | 4263 | 2170 | 1425 | 3623 | 3336 | 3153 |
| 17 | $3 \beta$-Hydroxy-4 $\alpha$-methylcholest-7-ene | Methostenol ${ }^{\text {b }}$ | 4310 | 2195 | 1435 | 3634 | 3341 | 3157 |
| 38 | $3 \beta$-Hydroxy-4,4', 14 $\alpha$-trimethyl-5 -cholesta-8,24-diene | Lanosterol | 4725 | 2410 | 1573 | 3674 | 3382 | 3197 |
| 19 | $3 \beta$-Hydroxy-24 $\alpha$-ethylcholest-5-ene | $\beta$-Sitosterol | 5002 | 2511 | 1634 | 3699 | 3399 | 3213 |
| 20 | $3 \boldsymbol{\beta}$-Hydroxy-4.4 ${ }^{\prime}$-dimethylcholest- 7 -ene |  | 6070 | 2568 | 1670 | 3783 | 3410 | 3223 |

[^3]TABLE V
CORRECTED RETENTION TIMESA $\boldsymbol{i}^{\prime} \boldsymbol{R}^{\prime}$ AND LOG $\boldsymbol{t}^{\prime} \boldsymbol{R}^{\prime}$ OF TRIMETHYLSILYL DERIVATIVES OF HYDROXYLATED STEROIDS ON JXR COLUMNS AT 215,230 AND $240^{\circ}$ GROUP D-MONOHYDROXY, MONOKETO COMPOUNDS

| No. | Compound | Trivial name | $10^{2} \times t^{\prime}{ }^{(m i n)}$ |  |  | $10^{3} \times \log t^{\prime}$ R |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ | $215{ }^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ |
| I | 3 $\beta$-Hydroxy-5 $\beta$-androstan-17-one |  | 458 | 275 | 201 | 2661 | 2439 | 2303 |
| 2 | $3 \alpha$-Hydroxy-5 $\alpha$-androstan-17-one | Androsterone | 462 | 278 | 202 | 2664 | 2444 | 2304 |
| 3 | $3 \alpha$-Hydroxy-5 $\beta$-androstan-17-one | Etiocholanolone | 485 | 288 | 207 | 2686 | 2459 | 2316 |
| 4 | $3 \beta$-Hydroxyandrost-5-en-17-0ne | DHA | 573 | 337 | 244 | 2758 | 2527 | 2387 |
| 5 | $3 \beta$-Hydroxy-5 $\alpha$-androstan-17-one | Epiandrosterone | 593 | 350 | 253 | 2773 | 2544 | 2403 |
| 6 | 3-Hydroxyestra-1,3,5(10)-trien-3-0ne | Estrone | 637 | 372 | 267 | 2804 | 2570 | 2421 |
| 7 | $17 \beta$-Hydroxy-5 $\alpha$-androstan-3-one | Allodihydrotestosterone | 642 | 378 | $27^{2}$ | 2807 | 2577 | 2434 |
| 8 | 17 $\alpha$-Hydroxyandrost-4-en-3-one | Epitestosterone | 660 | 387 | 278 | 2819 | 2587 | 2444 |
| 9 | $17 \beta$-Hydroxy-19-norandrost-4-en-3-one | 19-Nor-testosterone | 695 | 399 | 284 | 2842 | 2600 | 2453 |
| 10 | $3 \beta$-Hydroxy-5 $\beta$-pregnan-20-one | Pregnanolone | 732 | 434 | 308 | 2864 | 2638 | 2489 |
| II | $17 \beta$-Hydroxyandrost-4-en-3-one | Testosterone | 785 | 459 | 329 | 2895 | 2662 | 2517 |
| 12 | 3 $\alpha$-Hydroxy-5 $\beta$-pregnan-20-one | Epipregnanolone | 792 | 454 | 321 | 2898 | 2657 | 2506 |
| 13 | $17 \beta$-Hydroxypregna-r,4-dien-3-one |  | 865 | 503 | 358 | 2937 | 2701 | 2553 |
| 14 | $3 \beta$-Hydroxypregna-5,16-dien-20-one |  | 866 | 496 | 348 | 2937 | 2695 | 254 I |
| 15 | $3 \beta$-Hydroxypregn-5-en-20-one | Pregnenolone | 944 | 538 | 380 | 2975 | 2730 | 2580 |
| 16 | $3 \beta$-Hydroxy-5 $\alpha$-pregnan-20-one | Allopregnanolone | 973 | 553 | 389 | 2988 | 2742 | 2590 |
| 17 | 20 $\beta$-Hydroxy-5 $\alpha$-pregnan-3-one |  | 1140 | 644 | 454 | 3057 | 2809 | 2657 |
| 18 | 20f-Hydroxypregn-4-en-3-one |  | I44I | 799 | 552 | 3158 | 2899 | 2742 |

[^4]TABLE VI

| No. | Compound | Trivial name | $10^{2} \times t^{\prime}{ }_{R}(m i n)$ |  |  | $10^{3} \times \log t^{\prime}{ }_{R}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ |
| 1 | $3 \alpha, 17 \beta$-Dihydroxy- $5 \alpha$-androstane | Dihydroandrosterone | 586 | 339 | 241 | 2768 | 2530 | 2382 |
| 2 | 3f-17 $\chi^{\text {- Dihydroxyandrost-5-ene }}$ |  | 586 | 336 | 240 | 2767 | 2526 | 2380 |
| 3 | $3 \alpha, 6 \alpha$-Dihydroxy-5 $\beta$-pregnane |  | 645 | 367 | 258 | 2809 | 2564 | 2410 |
| 4 | $3 \beta, 17 \beta$-Dihydroxyandrost-4-ene | $\Delta^{4}$-Androstenediol | 695 | 401 | 282 | 2842 | 2602 | 2450 |
| 5 | 3R,16 6 -Dihydroxy-5 $\alpha$-androstane | 16x-Androstanediol | 698 | f01 | 282 | 2843 | 2602 | 2450 |
| 6 | $3 \beta, 17 \beta$-Dihydroxyandrost-5-ene | $\Delta^{5}$-Androstenediol | 724 | 415 | 294 | 2859 | 2618 | 2468 |
| 7 | 3,17 $\alpha$-Dihydroxyestra-1,3,5(10)-triene | $17 \alpha$-Estradiol | 728 | 414 | 289 | 2862 | 2617 | 2461 |
| 8 | 3¢,17p-Dihydroxy-5 $\alpha$-androstane |  | 736 | 426 | 300 | 2867 | 2628 | 2477 |
| 9 | 3,17 $\beta$-Dihydroxyestra-1,3,5(10)-triene | Estradiol | 809 | 460 | 322 | 2908 | 2663 | 2507 |
| 10 | 3¢,20 ${ }^{\text {a }}$-Dihydroxy-5 $\beta$-pregnane |  | 1006 | 564 | 393 | 3002 | 2751 | 2594 |
| 11 | $3 \alpha, 20 \beta$-Dihydroxy-5 $\beta$-pregnane |  | 1058 | 585 | 402 | 3024 | 2767 | 2604 |
| 12 | $3 \alpha, 20 x$-Dihydroxy-5 $\beta$-pregnane | Pregnanediol | 1154 | 634 | 437 | 3062 | 2802 | 2640 |
| 13 | $3 \beta, 20 \%$-Dihydroxypregna-5,16-diene |  | 10So | 599 | 414 | 3033 | 2777 | 2617 |
| 14 | $3 \beta, 20 \beta$-Dihydroxypregn-4-ene | Pregnenediol | 1238 | 687 | 470 | 3092 | 2837 | 2762 |
| 15 | $3 \beta, 20 \beta$-Dihydroxy-5 $\alpha$-pregnane |  | 1315 | 728 | 503 | 3118 | 2862 | 2701 |
| 16 | $3 \beta, 20 \alpha$-Dihydroxy-5 $\alpha$-pregnane |  | 1403 | 770 | 529 | 3147 | 2886 | 2723 |

${ }^{\text {a }}$ Operational conditions: cf. Table II.
J. Chromatog., 38 (1968) 439-459
TABLE VII
CORRECTED RETENTION TIMES $t^{\prime} \boldsymbol{f}^{\prime}$ AND LOG $t^{\prime} R$ OF TRIMETHYLSILYL DERIVATIVES OF HYDROXYLATED STEROIDS ON JXR COLUMNS AT 215,230 AND $240^{\circ}$

| No. | Compound | Trivial name | $10^{2} \times t^{\prime}{ }_{R}(\mathrm{~min})$ |  |  | $10^{3} \times \log t^{\prime}{ }_{R}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ | $215^{\circ}$ | $230^{\circ}$ | $240^{\circ}$ |
| 1 | $3 \alpha$-Hydroxy-5 $\alpha$-androstane-11,17-dione | 11-Ketoandrosterone | 583 | 346 | 250 | 2765 | 2539 | 2398 |
| 2 | $3 \alpha$-Hydroxy-5 $\beta$-androstane-11,17-dione | 11-Ketoetiocholanolone | 591 | 350 | 252 | 2771 | 2544 | 2402 |
| 3 | 12 $\alpha$-Hydroxy-5 $\beta$-pregnane-3,20-dione |  | 934 | 534 | 381 | 2970 | 2727 | 2581 |
| 4 | $3 \alpha$-Hydroxy-5 $\beta$-pregnane-1 1 ,20-dione |  | 1070 | 599 | 419 | 3029 | 2777 | 2622 |
| 5 | $3 \beta$-Hydroxy-5 $\alpha$-pregnane-11,20-dione |  | 1325 | 746 | 510 | 3122 | 2873 | 2708 |
| 6 | $11 \alpha$-Hydroxypregn-4-ene-3,20-dione | 11a-Hydroxyprogesterone | 1720 | 932 | 634 | 3235 | 2970 | 2 SO 2 |
| 7 | $11 \beta$-Hydroxypregn-4-ene-3,20-dione |  | 1995 | 1041 | 705 | 3299 | 3017 | 2848 |
| 8 | $30,6 x$-Dihydroxy- $5 \alpha$-androstan-1 7 -one |  | 692 | 390 | 274 | 2840 | 2591 | 2436 |
| 9 | $3 \alpha, 11 \beta$-Dihydroxy- $5 \alpha$-androstan-1 7 -one | 11 $\beta$-Hydroxyandrosterone | 753 | 437 | 311 | 2877 | 2640 | 2492 |
| 10 | $3 \alpha, 11 \beta$-Dihydroxy- $5 \beta$-androstan-17-one | i $\beta$-Hydroxyetiocholanone | 784 | 445 | 317 | 2894 | 2648 | 2502 |
| 11 | 3ק,17a-Dihydroxy-5 $\beta$-pregnan-20-one |  | 1090 | 609 | 425 | 3037 | 2785 | 2628 |
| 12 | $3 \alpha, 17 \alpha$-Dihydroxy-5 $\beta$-pregnan-20-one |  | 1097 | 614 | 430 | 3040 | 2788 | 2633 |
| 13 | $3 \alpha, 6 \alpha$-Dihydroxy-5 $\beta$-pregnan-20-one |  | 1135 | 617 | 430 | 3055 | 2790 | 2633 |
| 14 | 3p,17 $\beta$-Dihydroxypregn-5-en-16-one |  | 1128 | 628 | 435 | 3052 | 2798 | 2638 |
| 15 | $3 \beta, 16 x$-Dihydroxypregn-4-en-20-one |  | 1376 | 769 | 533 | 3138 | 2886 | 2727 |
| 16 | 3及,17 $\alpha$-Dihydroxy-5 $\alpha$-pregnan-20-one |  |  |  |  |  |  |  |
| 17 | 170,20 ${ }^{\text {d-Dihydroxypregn-4-en-3-one }}$ |  |  | 1337 |  |  | 3126 |  |
| 18 | 170,20x-Dihydroxypregn-4-en-3-one |  |  | 1391 |  |  | 3143 |  |
| 19 | $3 \alpha, 5 \alpha$-Dihydroxy-5 $\alpha$-cholestan-6-one |  | 7175 | 3560 | 2294 | 3855 | 3551 | 3360 |
| 20 | 3 $\beta$,1 $1 / \alpha$-Dihydroxy- $5 \alpha$-pregnane- 11,20 -dione |  |  |  |  |  |  |  |
| 21 | $3 \alpha, 17 \alpha$-Dihydroxy- $5 \beta$-pregnane-11,20-dione |  |  |  |  |  |  |  |
| 22 | II $\alpha, 17 \alpha$-Dihydroxypregn-4-ene-3,20-dione |  | 1416 |  |  | 3151 |  |  |

[^5]TABLE VIII

GROUP G-TRI-AND TETRAHYDROXY COMPOUNDS ${ }^{b}$

| No. | Compound | Trivial name and source ${ }^{\text {c }}$ | $10^{2} \times t^{\prime}{ }_{R}(m i n)$ | $10^{3} \times \log t^{\prime}{ }_{R}$ |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | $230^{\circ}$ | $230^{\circ}$ |
| 1 | 3,16x,17 $\beta$-Trihydroxyestra-1,3,5(10)-triene | Estriol | 846 | 2926 |
| 2 | $3 \beta, 17 \alpha, 20 \beta$-Trihydroxy- $5 \beta$-pregnane | Red. Fir, Table VII | 845 | 2926 |
| 3 | $3 \alpha, 17 \alpha, 20 \beta$-Trihydroxy-5 $\beta$-pregnane | S.R.C.: also Red. FI2 | 857 | 2933 |
| 4 | $3 \beta, 118,20 \beta$-Trihydroxy-5 $\beta$-pregnane | Red. Bio, Table III | 865 | 2936 |
| 5 | $3 \alpha, 11 \beta, 20 \beta$-Trihydroxy- $5 \beta$-pregnane | Red. F4 | 869 | 2939 |
| 6 | $3 \alpha, 17 \alpha, 20 \alpha$-Trihydroxy-5 $\beta$-pregnane | Pregnanetriol | $94{ }^{2}$ | 2974 |
| 7 | $3 \beta, 11 \alpha, 20 \beta$-Trihydroxypregn-4-ene | Red. F6 | 973 | 2988 |
| 8 | $30,1 i \beta, 20 \alpha$-Trihydroxy-5 $\beta$-pregnane | Red. Bro, $\mathrm{G}_{4}=$ main product | 984 | 2992 |
| 9 | $3 \beta, 17 \alpha, 20 \beta$-Trihydroxypregn-4-ene | Red. $\mathrm{F}_{7}$ | 1038 | 3016 |
| 10 | $3 \beta, 11 \beta, 20 \beta$-Trihydroxypregn-4-ene | Red. F7 | 1066 | 3028 |
| II | $3 \alpha, 11 \alpha, 20 \beta$-Trihydroxypregn-4-ene | Red. $\mathrm{F} 6, \mathrm{G}_{7}=$ main product | 1076 | 3032 |
| 12 | $3 \beta, 17 \alpha, 20 \alpha$-Trihydroxypregn-4-ene | Red. Fi9 | 1088 | 3037 |
| 13 | $3 \beta, 17 \alpha, 20 \beta$-Trihydroxy-50-pregnane | Red. F16 | 1117 | 3048 |
| $\mathrm{I}_{4}$ | $3 \beta, 11 \beta, 20 \beta$-Trihydroxy-5 $\alpha$-pregnane | Red. F5; also Red. $\mathrm{BI}_{12}$ | 1165 | 3066 |
| 15 | $3 \alpha, I I \beta, 20 \beta$-Trihydroxypregn-4-ene | Red. $\mathrm{F}_{7}$, Gıo $=$ main product | 1175 | 3070 |
| I6 | $3 \beta, 11 \beta, 20 \alpha$-Trihydroxy-5 $\alpha$-pregnane | Red. B12, G14 $=$ main product | 1287 | 3110 |
| 17 | $3 \alpha, 11 \beta, 17 \alpha, 20 \beta$-Tetrahydroxy-5 $\beta$-pregnane | also Red. F2I | 1248 | 3096 |
| 18 | $3 \alpha, 11 \beta, 17 \alpha, 20 \alpha$-Tetrahydroxy-5 $\beta$-pregnane | S.R.C. | 1416 | 3151 |
| 19 | $3 \alpha, 11 \alpha, 17 \alpha, 20 \beta$-Tetrahydroxypregn-4-ene | Red. F22 | 1638 | 3214 |

[^6]CORRECTED RETENTION TIMES ${ }^{a} t^{\prime} R^{\prime}$ AND LOG $t^{\prime} R$ OF TRIMETHYLSILYL DERIVATIVES OF HYDROXYLATED STEROIDS ON JXR COLUMNS AT 230 ${ }^{\circ}$

[^7]| No. | Compound | Trivial name and source ${ }^{\text {b }}$ | $10^{2} \times i^{\prime}{ }_{R}(m i n)$ | $10^{3} \times \log t^{\prime}{ }_{R}$ |
| :---: | :---: | :---: | :---: | :---: |
| 1 | 2r-Hydroxy-5 $\beta$-pregnane-3,20-dione |  | 957 | 2981 |
| 2 | 21-Hydroxypregn-4-ene-3,20-dione | Cortexone | $1340^{\text {c }}$ | 3127 |
| 3 | 11\%,21-Dihydroxypregn-4-ene-3,20-dione | Corticosterone | $2250^{\text {c }}$ | 3352 |
| 4 | 170,21-Dihydroxypregn-4-ene-3,20-dione | Cortexolone |  |  |
| 5 | 17 $\alpha$,21-Dihydroxy-5 $\beta$-pregnane-3,20-dione |  | c | c |
| 6 | 21-Hydroxypregn-4-ene-3,11-20-trione | 11-Dehydrocortisone | $1647^{\text {c }}$ | 3214 |
| 7 | II $\beta, 17 \alpha, 21$-Trihydroxypregn-4-ene-3,20-dione | Cortisol | c |  |
| 8 | 17 ${ }^{\text {, 21-Dihydroxypregn-4-ene-3,11,20-trione }}$ | Cortisone | c | c |
| 9 | $3 \beta, 17 \alpha, 21$-Trihydroxy-5 $\alpha$-pregnane-11,20-dione |  | c | c |
| 10 | $3 \alpha, 17 \alpha, 21$-Trihydroxy-5 $\beta$-pregnane-11,20-dione |  | $1074{ }^{\text {c }}$ | 303 I |
| 11 | 17 $\alpha, 21$-Dihydroxy-5 $\beta$-pregnane-3,11-20-trione |  | c | c |
| 12 | $3 \alpha, 17 \alpha, 20 \alpha, 21$-Tetrahydroxy-5 $\beta$-pregnan-11-one | S.R.C. | 2090 | 3320 |
| 13 | $3 \beta, 20 \beta, 21-T r i h y d r o x y-5 \beta$-pregnane | Red. HI | 1204 | 3080 |
| 14 | $3 \beta, 20 \beta, 21$-Trihydroxypregn-4-ene | Red. $\mathrm{H}_{2}$ | 1462 | 3165 |
| 15 | 3 $\beta, 17 \alpha, 20 \beta, 21$-Tetrahydroxy-5 $\beta$-pregnane |  | 1728 | 3238 |
| 16 | $3 \beta, 17 \alpha, 20 \beta, 21-T e t r a h y d r o x y p r e g n-4-$ ene | S.R.C. also Red. $\mathrm{H}_{4}$ | 2100 | 3320 |
| 17 | $3 \beta, 11 \beta, 20 \beta, 21-T e t r a h y d r o x y p r e g n-4-$ ene | Red. H3, also Red. H6 | 2254 | 3354 |
| 18 | $3 \alpha, 11 \beta, 17 \alpha, 20 \alpha, 2 \mathrm{I}-\mathrm{Pentahydroxy-5} \beta$-pregnane | S.R.C. also Red. Hir | 2436 | 3387 |
| 19 | $3 \alpha, 11 \beta, 17 \alpha, 20 \beta, 21-P e n t a h y d r o x y-5 \beta$-pregnane | also Red. Hio | 2528 | 3403 |
| 20 | $3 \beta, 11 \beta, 17 \alpha, 20 \beta, 21-P e n t a h y d r o x y-5 \beta$-pregnane | also Red. Hin | 2544 | 3404 |
| 21 |  | Red. H7, also Red. H8 | $3180$ | $3502$ |
| 22 | $3 \beta, 11 \beta, 17 \alpha, 20 \beta, 21$-Pentahydroxy-5 $\alpha$-pregnane | S.R.C. also Red. H9 | 3520 | 3547 |
|  | perational conditions: cf. Table II. mpounds 7 to $11,16,19$ and 20 were obtained fro ed as Red. followed by letter and number, have be H of this table. composition-All compounds from 12 to 22 are po | nc.; S.R.C. = Steroid Re reduction of the steroid <br> oids whose TMS derivati | ompounds the ample: $\mathrm{H}_{2}=$ | urce of wh roid numb |

TABLE X
 and pregnane ( P ) SERIES

| Group | With | A-Ring fealures |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $5{ }^{\text {a }}$ | $5 \beta^{\text {a }}$ | 5 $\beta, 3 \beta$ | $5 \alpha, 3 \alpha$ | ${ }_{5} \beta, 3 K$ | $5 \beta, 3 \alpha$ | $5 \alpha, 3 K$ | $5 \alpha, 3 \beta$ | $\Delta^{4}, 3 \beta$ | $\Delta^{4}, 3 K$ | $\Delta^{5}, 3 \beta$ | $\Delta^{1,4}, 3 K$ |
| A |  | 1924 | $\mathrm{I}^{8} 87$ | 2175 | 2178 | 2190 | 2194 | 2227 | 22 So | 2255 | 2322 | 2264 | 2359 |
| P |  | 2150 | 2113 | 2401 | 2404 | $24^{16}$ | 2420 | 2453 | 2506 | 2481 | 2548 | 2490 | 2585 |
| $11 \alpha$ | P |  |  |  |  |  |  |  |  | 153 | 178 |  |  |
| $11 \beta$ | $\mathbf{P}$ |  |  | 170 |  |  | 170 |  | 203 | 193 | 226 |  |  |
| 16\% | $A^{\text {b }}$ |  |  |  |  |  |  |  | 322 |  |  |  |  |
| 170 | $\mathrm{A}^{\text {b }}$ or Pb | 260 | 260 | 260 | 260 | 260 | 260 | 260 | 260 | 260 | 260 | 260 | 260 |
| $17 x$ | $A^{\text {b }}$ or $\mathrm{Pb}^{\text {b }}$ | 350 | $35^{\circ}$ | $35^{\circ}$ | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | $35^{\circ}$ |
| 20\% | $\mathrm{Pb}^{\mathbf{b}}$ | 380 | 380 | 380 | 380 | 380 | 3 So | 380 | 380 | 3 So | 3 So | 380 | 380 |
| $20 \beta$ | Pb | 354 | 354 | 354 | 354 | 354 | 354 | 354 | 354 | 354 | 354 | 354 | 354 |
| 17 ${ }^{1}$,20 | P |  |  |  |  |  | 554 |  |  | 556 | 595 |  |  |
| $17 \alpha, 20 \beta$ | P |  |  | 526 |  |  | 512 |  | 539 | 535 | 578 |  |  |
| 17 ${ }^{1}$,2015 | P |  |  | $3^{8} 4$ |  |  | 368 |  | 391 |  | 425 |  |  |
| 1 IK | A |  |  |  | 90 |  | 90 |  |  |  |  |  |  |
| nk | P |  |  |  |  |  | 118 |  | 118 |  |  |  |  |
| 17li | A or Pi) | 266 | 266 | 266 | 266 | 266 | 266 | 266 | 266 | 266 | 266 | 266 | 266 |
| 20 K | Pb | 243 | 243 | 243 | 243 | 243 | 24.3 | 243 | 243 | 24.3 | 243 | 243 | 243 |
| 21-OH | 2ol3 ${ }^{\circ}$ | 335 | 335 | 335 | 335 | 335 | 335 | 335. | 335 | 335 | 335 | 335 |  |
| $2 \mathrm{I}-\mathrm{OH}$ | $20 \beta^{1 \prime}$ | 315 | 315 | 315 | 315 | 315 | 315 | 315 | 315 | 315 | 315 | 315 |  |
| 21-OH | $17 \alpha, 20 \beta$ | 305 | 305 | 305 | 305 | 305 | 305 | 305 | 305 | 305 | 305 | 305 |  |
| $21-\mathrm{OH}$ | 17x,203 | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 215 |  |

[^8]TABLE XI
calculated and experimental corrected retention timesa $t^{\prime}$ r at $230^{\circ}$ for diols of the androstane (A) and preginane (1) series

| Diol (TMS) | $t^{\prime} n\left(0^{-2} \mathrm{~min}\right)$ |  | Diol (TMS) | $t^{\prime} n\left(x 0^{-2} \mathrm{~min}\right)$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Calculated | Experindental |  | Calculated | Experimental |
|  | 272 |  | $5 \beta \mathrm{P}-3 \beta, 20 \beta$ - | 567 | $56_{4}$ |
| $5 \alpha A-3 \alpha, 17 \alpha-$ | 274 |  | $5 \alpha^{P} \mathrm{P}-30,20 \beta-$ | 573 |  |
| 5 $\beta$ A-3 $\alpha, 17 \alpha-$ | 284 |  | 5 $\beta^{2} \mathrm{P}-3 \alpha, 20 \beta-$ | 593 | 585 |
| ${ }^{4} A-3 \beta, 17 c \alpha$ | 327 |  | 5 $\beta$ P-3 $\beta$, $20 \alpha$ | 603 |  |
| $5 \beta A-3 \beta, 17 \beta-$ | 335 |  | $50 \mathrm{P}-3 \alpha, 20 \alpha-$ | 608 |  |
| $4^{5} \mathrm{~A}-3 \beta$, т $7 \alpha$ - | 335 | 336 | $5 \beta \mathrm{P}-3 \alpha, 20 \alpha-$ | 631 | 630 |
| ${ }_{5 \alpha} \alpha_{\text {A }} \mathrm{A}-3 \alpha, 17 \beta-$ | 338 3 | 339 | $4^{4} \mathrm{P}-3 \beta, 20 \beta-$ $4^{5} \mathrm{P}-3,20 \beta-$ | 684 692 | 686 |
| $56 A$ A-3 $\beta, 17 \alpha-$ $5 \beta$ - $3 \alpha, 17 \beta-$ | 349 350 |  | $\Lambda^{5} P-3 \beta, 20 \beta-$ $5 \propto-3 \beta, 20 \beta-$ | 692 730 | 73 |
| ${ }^{4} A N-3 \beta, 17 \beta-$ | 350 4 | 40 t | ${ }_{14 \mathrm{P}-3 \beta, 20 \alpha-}$ | 726 | 73 |
| $\angle^{5} A-3 \beta-\mathrm{t} 7 \beta^{-}$ | 412 | 415 | $4^{5} \mathrm{P}-3 \beta, 20 \alpha-$ | 742 |  |
| 5*A-3 $\beta$, $78 \cdots$ | 430 | 426 | $5 \alpha \mathrm{P}-3 \beta, 20 \alpha-$ | 774 | 770 |

${ }^{n}$ Operational conditions: cf. Table [1.
"Cf. Table VI.
packing density, yet caused breakdown of particles and exposure of unsilanized material cletrimental to the performance of the columns.

The absence of gas flow during the first stages of conditioning (Table I) presumably allowed condensation of vaporized stationary phase on the column wall and prevented movement of vaporized phase toward the column exit. Heating under these conditions would at first promote a more even distribution of phase within particles, then further polymerization of JXR on both support and column wall. Eventually, fully polymerized stationary phase could no longer be displaced even under high gas flow at high temperature.

In routinely obtained chromatograms examplified in Fig. 2, peaks were generally symmetrical. Response to small amounts of steroid injected was excellent; decrease in response was appreciable at the low nanogram level only. This effect was reproducible and amenable to precise calibration.

Several duplicates of the columns prepared and conditioned in the manner described have been prepared in this and other laboratories. All showed properties identical to those of the 3 -year old column pair in effecting separations demonstrated in Tables II to IX: relative retention times were the same and incremental factors listed in Tables X and XII were applicable in all cases. The only variations observed were small; they concerned the number of theoretical plates (from 5400 to 5700 for cholesterol) and the temperatures at which the listed values of relative retention times were obtained. These temperatures varied from column to column within a range of about $2^{\circ}$ and must be regarded as life-time characteristics of each column.

Curtailing the conditioning schedule shown in Table I did not seem to modify retention time characteristics appreciably; it did, however, reduce the separating power in two ways: the number of theoretical plates was decreased and some tailing of peaks became apparent particularly when initial heating in the absence of gas flow was shortened.

TABLE XII
CALCULATED VALUES OF IO $\times$ LOG $t^{\prime} \cap$ ON JXR COLUMAS UNDER STANDARD CONDITIONS (TABLE IV) FOR STRUCTURAL FEATURES OF STEROLS
$10^{3} \times \log t^{\prime} n=3197^{\mathrm{a}}+10^{3} \times \Delta \log t^{\prime} n^{\mathrm{b}}$ 。

|  | $C 27$ | 28 | 29 | 29 | 28 | 28 | 30 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | - | $I_{4} \times M e$ | $\begin{aligned} & I 4 \alpha M e \\ & 1 \propto M e \end{aligned}$ | $\begin{aligned} & 14 \alpha M e \\ & 24 M e c \end{aligned}$ | $40 M e$ | $2.4 M e^{\mathrm{c}}$ | $\begin{aligned} & 4.4^{\prime M e} \\ & 1.40 M e \end{aligned}$ |
|  | $\boldsymbol{T}$ | 2 | 3 | 4 | 5 | 6 | 7 |
| (a) $5: 202$ | $-74.3$ | -ro3 | $-7$ | 12 | 22 | 40 | 64 |
| (b) $5: 8: 22$ | $-54$ | - 92 | 4 | 22 | 32 | 51 | 74 |
| (c) 22 | -64 | - 92 | 4 | 22 | 32 | 51 | 74 |
| (d) $8: 22$ | $-53.6$ | - 82 | 14 | 32 | 42 | 61 | 85 |
| (e) $5: 7: 22$ | $-33.3$ | - 61 | 35 | 53 | 63 | 80 | 105 |
| (f) $7: 22$ | -r 7.7 | - 46 | 50 | 63 | 78 | 96 | 121 |
| (g) 5 | - 10.4 | - 39 | 57 | $7^{6}$ | 86 | 104 | 128 |
| (h) | $\bigcirc$ | $-28.3$ | $+67.7$ | 86.4 | 96.0 | II4.7 | r 38.3 |
| (i) $5: 8$ | - | - 28 | 68 | 86 | 96 | 115 | $13^{8}$ |
| (j) 8 | $+10.3$ | - 18 | 78 | 96 | 106 | 125 | r 49 . |
| (k) $5: 24$ | 26.7 | $-2$ | 94 | 112 | 123 | 14 I | 165 |
| (1) $5: 7$ | 30.8 | + 2 | 98 | Ir 6 | 127 | 146 | 169 |
| (m) 24 | 37.0 | 9 | 105 | 123 | 133 | 152 | r 75 |
| (17) $5: 8: 24$ | 37.0 | 9 | 105 | 123 | 133 | 152 | 175 |
| (0) 7 | 46.3 | 18 | II4 | 133 | 142 | 161 | 185 |
| (p) $8: 24$ | 47.3 | 19 | 115 | I 34 | 143 | 162 | 186 |
| (q) $5: 7: 24$ | 67.8 | 40 | 136 | I54 | 164 | IS3 | 206 |
| (r) $7: 24$ | 83.4 | 55 | I5I | 170 | 179 | 198 | 222 |

[^9]The longevity of columns undoubtedly stems also from factors other than preparation and conditioning. Among these the proportion of JXR to support ( $3 \%$ by weight) is high by comparison with columns generally used for the GLC of steroids. In addition, consistent operation at a very low level of injected material would tend to minimize interactions with the liquid phase of steroids and their thermal decomposition products which tend to affect the stability and separation characteristics of the packing material. Observations at low attenuation following injections clearly showed a considerable increase in the persistence of residual background with increased quantity injected: both residence time and amounts of decomposition products were thereby very much increased. Hence the rate and extent of physical modification of the stationary phase by thermal breakdown products and by polymeric material arising from these products were greatly minimized at the level of injected material used in the present work.

As shown in Fig. 2, low background and stability were obtained by injecting nanogram amounts at very low attenuation. As shown in Part III of this series, precise quantifications were routinely achieved at these levels. The method is therefore entirely suitable for the analysis of very low concentrations of steroids found in most biological materials.

Samples of biological origin invariably contain amounts of extraneous material

| 29 | 30 | 29 | 29 | 31 | 30 | 30 | 32 | $3 T$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $4.4{ }^{\prime} M e$ | $\begin{aligned} & 1.4 \alpha M e \\ & 24 E t \mathrm{c} \end{aligned}$ | $\begin{aligned} & 4 \propto M e \\ & 24 M e \end{aligned}$ | $2.4 E t \mathrm{c}$ | $\begin{aligned} & 4.4^{\prime} M e \\ & 14 \alpha M e \\ & 24 M e c \end{aligned}$ | $\begin{aligned} & 4,4 M e \\ & 24 M e^{\circ} \end{aligned}$ | $\begin{aligned} & 4 \alpha M E \\ & 24 E t \mathrm{c} \end{aligned}$ | $\begin{aligned} & 4.4 M e \\ & 14 \alpha M e \\ & 24 E t c \end{aligned}$ | $\begin{aligned} & 4,4^{\prime} M E e \\ & 24 E t{ }^{\circ} \end{aligned}$ |
| 8 | 9 | ro | IT | I2 | 13 | 14 | 15 | 16 |
| 92 | III | 136 | 140 | 179 | 207 | 236 | 278 | 306 |
| 103 | 122 | 147 | 150 | 189 | 2 I 7 | 246 | 288 | 317 |
| 103 | 122 | 147 | 150 | 189 | 217 | 24.6 | 288 | 317 |
| II3 | 132 | 157 | 160 | 199 | 227 | 256 | 298 | 327 |
| I 33 | ${ }^{5} 5$ | 178 | 181 | 220 | 2.48 | 277 | 319 | 348 |
| $\mathrm{I}_{49}$ | 168 | 193 | 196 | 235 | 263 | 292 | 334 | 363 |
| 156 | I 75 | 201 | 204 | 243 | 271 | 300 | 342 | 370 |
| 166.6 | 185.7 | 210.7 | 214 | 253 | 281.3 | 310.0 | 352.3 | 380.6 |
| 167 | r86 | 211 | 214 | 253 | 281 | 310 | 352 | 381 |
| 177 | 196 | 221 | 224 | 263 | 291 | 320 | 362 | 391 |
| 193 | 212 | 237 | 241 | 280 | 308 | 337 | 378 | 4.07 |
| 197 | 217 | 242 | 245 | 2 S 4 | 312 | 340 | 383 | 4 II |
| 204 | 223 | 248 | 251 | 290 | 318 | 347 | 389 | 417 |
| 204 | 223 | 248 | 251 | 290 | 318 | 347 | 389 | 417 |
| 213 | 232 | 257 | 260 | 299 | 328 | 356 | 399 | 426 |
| 214 | 233 | 258 | 261 | 300 | 329 | 357 | 400 | 427 |
| 234 | 254 | 280 | 282 | 321 | 349 | 382 | 420 | 448 |
| 250 | 269 | 294 | 297 | 336 | 365 | 393 | 436 | 463 |

often far in excess of the complex steroid mixtures to be analyzed. Quantification thus generally requires preliminary clean-up processes as well as preliminary fractionation procedures. The systematic use of TLC ${ }^{1-8}$ allows both these requirements to be met. Injection of "clean" samples obtained from TLC plates undoubtedly contributed to the longevity of the present columns by minimizing possible interactions of the stationary phase with extraneous materials, their thermal breakdown and polymeric products. In four years of uninterrupted use neither the injection port, nor the detector of the P.E. 800 chromatograph has required cleaning.

The use of $\mathrm{CS}_{2}$ as a solvent for TMS derivatives may have contributed to the maintenance of column characteristics. Among advantages derived from the use of $\mathrm{CS}_{2}$ which have been discussed by one of $\mathrm{us}^{11,12}$, the abolition of solvent trailing (Fig. 2) and the ability of $\mathrm{CS}_{2}$ to dissolve TMS derivatives and reaction products (cf. above) are noteworthy. In addition, this solvent shows little affinity for most stationary phases and therefore, will not cause much physical alteration of the packing material.

TMS derivatives ${ }^{13}$ in contrast to others ${ }^{1,2}$ are of general application in the GLC of steroids. With the present method, complete conversion of most steroids was obtained in 3 h at room temperature ${ }^{1,2}$. Very few steroids required longer reaction times; among these, estriol required to h . It should be noted that some steroids are
sensitive to direct contact with dimethylsilylchloride. With these, reversing the order of addition of reagents (cf. above) will lead to abnormal products.

Trace amounts of unreacted trimethyldisilazane in the final procluct could have beneficial effects in eliminating "active sites' within the column ${ }^{1,2}$. The injection of large amounts of this compound does, however, undesirably modify column characteristics. The high separating power of the present columns partly resulted from the use of roo-r 20 mesh Gas Chrom $Q^{14}$. With another silanized support the number of theoretical plates per foot was 500 at best ${ }^{1,2}$ although mesh size, percentage JXR and conditioning were identical.

JXR, a dimethylsilane polymer is more stable thermally than the analogous phase SE 30. Our experience with OVI is too limited to warrant an estimation in this respect. Separation characteristics of the three phases were similar yet appreciably different. Differences observed with OVI did not confer advantages to this phase over JXR in the present type of work.

Although longer, more efficient columns can undoubtedly be prepared by the present procedure, their use is restricted by present instrumental limitations in permitting required high carrier-gas fore-pressures. Internal flow control systems would have to be changed or by-passed. Longer columns have a significant damping effect on pressure changes which could obviate the need for an internal control system. With 20-ft. columns, the number of theoretical plates could be at least 10,000 . However, residence time of steroids in such columns would be twice that in $9-\mathrm{ft}$. columns for the same flow rate: thermal destruction at low level of steroids may then become significant.

The stability of $\Gamma M S$ derivatives in $\mathrm{CS}_{2}$ solutions has been discussed ${ }^{1,2}$. Under the conditions described, retention times of TMS derivatives obtained with standard solutions prepared three years ago and used repeatedly over this period did not vary; hence the columns characteristics remained constant in spite of extensive use involving many thousands of injections during this period. The thermal stability of these derivatives under present GLC conditions was generally excellent. Among the few that were unstable (Tables VII and IX), some produced well defined peaks; however, the retention times clearly corresponded to compounds of smaller molecular size produced by decomposition. In other cases, several overlapping peaks emerged in close succession. The instability of unsaturated 2 I-corticosteroids including the steroid hormones is well known ${ }^{15}$. Treatment of all these steroids with sodium borohydride, under conditions to be described in a forthcoming publication, resulted in their quantitative conversion to polyhydroxysteroids whose TMS derivatives could be readily chromatographed (Tables VIII and IX). The retention times of the reduced steroids (TMS) were distinct and specific. Polyhydroxylated steroids thus obtained could also be converted to halogenated derivatives suitable for quantification by electron capture.

The choice of standard temperatures used in the present study was governed by the following consideration. Mixed steroids generally obtained from biological material could be adequately separated at $230^{\circ}$; at this temperature a complete chromatogram was usually obtained in 30 min. With urinary steroid hormones and metabolites a somewhat better separation resulted at $215^{\circ}$ in 30 min . On the other hand, the GLC of high molecular weight sterols from molds, bacteria or algae, and also reduced 2 I-corticosteroids could be achieved more readily at $240^{\circ}$. Operation at $230^{\circ}$ was adequate in all cases.

The sensitivity of retention times to temperature changes explains the necessity for precisely controlled oven temperature. Under the described set of conditions, very little change could be observed in retention times. That of cholestane, for example, never varied by more than $\pm 0.02 \mathrm{~min}( \pm 0.3 \%)$ in several hours.

From the data in Tables II to VII the accuracy of the following relation can be demonstrated for all steroids:

$$
\begin{equation*}
\mathrm{IO}^{3} \times \log t^{\prime} M=A_{i}+\mathrm{IO}^{3} \times B_{i} T^{-1} \tag{I}
\end{equation*}
$$

where $A_{i}$ and $B_{i}$ are constants indepenclent of $T$, the absolute temperature.
A similar relation can be found for standard steroids included in a mixture, hence:

$$
\begin{equation*}
10^{3} \times \log t^{\prime} R s=A_{s}+10^{3} \times B_{s} T^{-1} \tag{2}
\end{equation*}
$$

From equs. (I) and (2) the following expression

$$
\begin{equation*}
\mathrm{I}^{3} \times \log t^{\prime} n i / t^{\prime}{ }_{1 s}=A_{i}-A_{s}+\left(B_{i}-B_{s}\right) T^{-1} \tag{3}
\end{equation*}
$$

is obtained for the relative retention time $t^{\prime} R l / t^{\prime} R s$ of a given steroid. Since this is a constant for a given temperature within a relatively wide range of carrier gas flow rates,

$$
\begin{equation*}
\bar{A}(i, s)=A_{i}-A_{s} \text { and } \bar{B}(i, s)=B_{i}-B_{s} \tag{4}
\end{equation*}
$$

are constants independent of both temperature and carrier gas flow rate. Hence accurate determinations of relative retention times at two temperatures give access to specific constants $\bar{A}(i, s)$ and $\bar{B}(i, s)$ by which unlsnown steroids can be identified with considerable certainty. Use of these factors, for which we suggest the name of Retention Constants (R.C.), will be described in detail in Part II of the present series.

Incremental factors listed in Tables $X$ and XII are simply additive. When corresponding functional groups or features are sufficiently separated in the molecule to prevent a crowding effect, the values apply in all cases; thus values for $17 \alpha-h y-$ droxy, $\boldsymbol{\text { f }} \beta$-hydroxy, and all other values which are repeated in every column of Table X indicate inclependence of the corresponding features on the presence of other groups. Values for $I I \alpha-$ and $I I \beta$-hydroxy do not show this independence since they vary with different A-ring features; the value for 21 -hydroxy depends on the nature of neighboring C2o or D-ring substitution. A crowding effect is indicated by aggregate values for $I 7 \alpha, 20 \alpha ; I 7 \alpha, 20 \beta ; 17 \alpha, I o K$, etc. being smaller than the sum of values for component functional groups taken singly.

With the values listed in Tables X and XII, most retention times can be predicted within $\pm \mathrm{I} \%$. Discrepancies higher than $2 \%$ are exceptional. Table XI lists calculated and observed values for the TMS derivatives of androstane- and pregnanediols. Discrepancies observed with sterols (Table XII) are even lower.

No values corresponding to $\Delta^{4}, 3 \alpha$ are given in Table $X$ since a determination for this group in the absence of crowding effect awaits the availability of suitable compounds. However, at least three compounds which include this A-ring feature are listed as GII, GI5 and GIg in Table VIII. If incremental values listed under
$\Delta^{4}, 3 \beta$ in Table X for other groups included in these compounds are used, a value of 2525 for $\Delta^{4}, 3 \alpha$ (pregnane) is found.in all cases. Hence it is probable that values listed in Table $X$ for $\Delta^{4}, 3 \beta$ apply to $\Delta^{4}, 3 \alpha$ also, and that 2525 is the value for $\Delta^{4}, 3 \alpha$ (pregnane).

It should be noted that in the two first lines of Table X, aggregate values have been entered for convenience. Each of the values listed in these lines corresponds to a sum, including either 1924 ( $5 \alpha$-androstane, of. column 3) or 2150 ( $5 \alpha$-pregnane, of. column 3) with the specific value for each A-ring feature; for example, in column 5 , $2175=1924+251$ and $2401=2150+251$; in column $6,2178=1924+254$ and $2404=2150+254 ;$ in column $7,2190=1924+266$ and $2416=2150+266 ;$ etc. Hence the specific increment corresponding to each A-ring feature is the same for compounds of both androstane and pregnane series.

These and other increments also apply to compounds of the cholestane, or C series. A comparison of incremental values found for the $C$ series with corresponding values in the androstane ( A ) and pregnane ( P ) series shows the following correspondences: $5 \alpha \mathrm{C}, 3 \mathrm{~K}=310(5 \alpha \mathrm{~A}, 3 \mathrm{~K}=5 \alpha \mathrm{P}, 3 \mathrm{~K}=307$ ) ; $5 \alpha \mathrm{C}, 3 \beta=363(5 \alpha \mathrm{~A}, 3 \beta=$ $5 \alpha \mathrm{P}, 3 \beta=355) ; 5 \beta \mathrm{C}, 3 \mathrm{~K}=265(5 \beta \mathrm{~A}, 3 \mathrm{~K}=5 \beta \mathrm{P}, 3 \mathrm{~K}=269) ; 5 \beta \mathrm{C} ; 3 \alpha=270(5 \beta \mathrm{~A}, 3 \alpha=$ 270) ; $5 \beta \mathrm{C}, 3 \beta=255(5 \beta \mathrm{~A}, 3 \beta=5 \beta \mathrm{P}, 3 \beta=248)$. Note that 114.7 being the value for methyl in the chain (Table XII, 24 Me ), $6 \times 114.7=688$. Hence the increment for $5 \alpha \mathrm{C}$ should be 2150 (pregnane) $+688=2838$. The value found for $5 \alpha \mathrm{C}$ is 2833 .

Independent incremental factors of $\log t^{\prime}{ }_{R}$ were observed with nonpolar stationary phases only. Polar phases induce phase-steroid interactions which vary in extent with each different configuration. Since values of incremental factors vary with each structural situation, accurate prediction of retention times from structural features is impossible with polar phases.

It is generally believed that separations on nonpolar phases are induced mainly by differences in molecular weight. Furthermore, the name selective is applied to polar columns to indicate a greater sensitivity to differences in structural features. This appellation is misleading. The data presented in Tables II to XII undoubtedly show considerable discrimination by nonpolar JXR columns of subtle structural differences (cf. Table XI, for example). The common belief that polar phases have generally useful selective properties is likewise unfounded since such polar phases do not allow many separations which are readily achieved with nonpolar phases.

Use of TLC as a preliminary step in the separation of steroids affords a means of effecting a complementary separation on the basis of polarity. Zones containing steroids differing as to the number of carbonyl and hydroxy groups, and subzones containing steroids of different stereoconfiguration are sharply separated on TLC plates ${ }^{1-5}$. The problem of locating the center of any given zone or subzone within $\pm$ I mm has been solved in this laboratory by including several pilot dyes in the mixture analyzed and relating the position of interest to that of the nearest dye pair. A forthcoming paper ${ }^{18}$ on this procedure will demonstrate that steroids which are poorly separated on JXR columns migrate in separate TLC subzones which can be independently removed from the plates and quantified by GLC. Such is the case, for example with several pairs of compounds listed in Table V: etiocholanolone (D2)
 (DI5) and allopregnanolone (DI6).

In addition, silver nitrate TLC ${ }^{16}$ permits preliminary separations on the basis of differences in unsaturation. Hence separation problems generally believed to
require the use of polar columns can be solved by the combination of TLC with GLC on high-efficiency JXR columns.

## ACKNOWLEDGEMENTS

The technical assistance of Mr . R. Cochrane was very much appreciated. We are grateful to Dr. R. Fumagalili and Dr. G. Galli of the Institute of Pharmacology, Milan, Italy, and to Professor W. Kıyne and Dr. N. Kirk of Westfield College, London, Administrators of the Steroid Reference Collection, for the supply of several steroid samples.

## REFERENCES

r F. A. Vandenheuvel, Sympositum on Quantitative Methodology in Lipid Research, Pennsylvania State University, Aug. 3-7, 1964.
2 F. A. Vandenheuvel, G. J. Hinderiss and J. C. Nixon, J. Am. Oil Chemists' Soc., 42 (1965) 283.

3 F. A. Vandenheuvel, Symposium on Modern Lipid Methodology, Claremont, Calif., Aug. 9-13, 1965.

4 F. A. Vandenheuvel, Second International Course on Methods for Lipid Research, Milan, Italy, Sept. 16-25, 1965.
5 F. A. Vandenheuvel, Can. J. Biochem., 45 (1967) 191.
6 F. A. Vandenheuvel, J. Chyomatog., 25 (1966) 102.
7 A. Kursis, in D. Glick (Editor), Methods of Biochemical Analysis, Vol. XIV, Interscience, New York, 1966, p. 442-447.
8 F. A. Vandenheuvel, J. Lab. Clin. Med., 69 (1967) 343.
9 B. A. Inights and G. H. Thomas, Natueve, 194 (1962) 833.
to G. Gallitand S. Maroni, Steroids, io (1967) I89.
I F. A. Vandenheuvel, A nal. Chem., 35 (1963) 1193.
I2 F. A. Vandenheuvel, Anal. Chem., 36 (1964) 1930.
i 3 t. LuUkainen, W. J. A. Vandenheuvel, E. O. Haati and E. C. Horning, Biochim. Biophys. Acta, 52 (1961) 599.
14 W. R. Supina, R. S. Henly and R. F. Fruppa, J. Am. Oil Chemists' Soc., 43 (1966) 202A.
15 I. Merirs, J. Lipid Res., 3 (1962) 126.
i6 N. Pelici, T. L. Wilson, M. E. Mif.ler and F. M. Angeloni, J. Am. Oil Chemists' Soc., 42 (1965) 393.

17 F. A. Vandenheuvel and A. S. Court, J. Chromatog., in press.
18 F. A. Vandenheuvel, J. Chromalog., 38 (1968) 373.


[^0]:    ${ }^{*}$ Contribution No. 318 from the Animal Research Institute.
    ** Present address: Department of Agriculture, Research Station, Fredericton, New Brunswicle (Canada).

[^1]:    ${ }^{\text {a }}$ Helium flow rates through the columns must first be adjusted to the same value, i.e., 60 $\mathrm{ml} / \mathrm{min}$ (bubble meter). Thus both columns have been flushed with, and are full of helium when cut-off valve is turned off to begin conditioning.
    ${ }^{5}$ Changes in temperature must be gradual over the period indicated.

[^2]:    a Operational conditions: Inlet temperature, $270^{\circ}$; detector $=$ oven temperature. Inlet pressure 1 romatographer, 60 lb .; helium flow rate, $60 \mathrm{ml} / \mathrm{min}$. Hyclrogen inlet pressure, I 8 lb ; air, 50 lb .

[^3]:    a Operational conditions: cf. Table II.
    b Samples obtained from Fumagalli, confirmed by mass spectrum by Galli and Maroni ${ }^{10}$.

[^4]:    a Operational conditions: cf. Table II.

[^5]:    ${ }^{\text {a }}$ Operational conditions: of. Table II.
    b More of these compounds are listed wiht 21-hydroxy corticosteroids, Table IX.
    ${ }^{\text {e }}$ Some decomposition; the reduced compounds chromatograph very well: cf. Table VIII, Gı6, Gı8.

[^6]:    ${ }^{\text {a }}$ Operational conditions: cf. Table II. ${ }^{6}$ More of these compounds and also pentahydroxysteroids are listed among 21-hydroxycorticosteroids in Table IX. c Estriol and pregnanetriol obtained from Steraloids; S.R.C. = Steroid Reference Collection. Compounds the source of which is indicated as Red.
    followed by a letter and number, have been obtained by reduction of the steroid thus designated. Example: F2 is compound No. 2 in Group $F$ (Table VII).

[^7]:    GROUP H—2I-HYDROXYCORTICOSTEROIDS

[^8]:    a No other feature in A-ring. b No substitution in D-ring.

[^9]:    ${ }^{\mathfrak{a}} 3197=10^{3} \times \log ^{\prime} t_{R}$ of $3 \beta$-hydroxy-5 $\alpha$-cholestane (cholestanol) at $230^{\circ}$ under the same conditions.
    ${ }^{-}$Example: Compound art is $3 \beta$-hydroxy-24 $\beta$-ethylcholesta-5,22-diene (stigmasterol) :10 $\times \log ^{\prime} t^{\prime} \pi=$ $3197+140=3337$. The experimental value for stigmasterol (Table IV, CI6) is 3336 .
    o $\alpha$ or $\beta$.

